{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/prescribing-information/miconazole-oral-gel/","result":{"pageContext":{"chapter":{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel","depth":2,"htmlHeader":"<!-- begin field 60ffdc07-e7c6-43c6-81b7-86710f0f96be --><h2>Miconazole oral gel</h2><!-- end field 60ffdc07-e7c6-43c6-81b7-86710f0f96be -->","summary":"","htmlStringContent":"<!-- begin item bae33734-0692-4d57-8e11-535e3d55f95d --><!-- end item bae33734-0692-4d57-8e11-535e3d55f95d -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"800e543f-aa34-535b-982f-b67228787534","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"55390d7e-e362-58db-a676-0799bad13ee4","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 62214a46-606f-4376-a849-a76000a20ab8 --><h3>What are the licensed doses?</h3><!-- end field 62214a46-606f-4376-a849-a76000a20ab8 -->","summary":"","htmlStringContent":"<!-- begin item 52200db4-9712-4d03-a2b7-a76000a20b1b --><!-- begin field 6f406926-0668-4139-ae2e-a76000a20ab8 --><ul><li><strong>Miconazole oral gel (24 mg/mL) </strong>is indicated for the treatment of fungal infections of the oropharynx and gastrointestinal tract (unlicensed for use in a child aged younger than 4 months, or 5–6 months for an infant born pre-term).</li><li><strong>The licensed doses for oral candidiasis are:</strong><ul><li>Children aged 4–24 months — 1.25 mL (1/4 measuring spoon) of gel applied four times a day after meals. <ul><li>Each dose should be divided into smaller portions, and the gel should be applied to the affected area(s) with a clean finger.</li><li>The gel should not be applied to the back of the throat due to possible choking. </li></ul></li><li>Adults and children 2 years of age and older — 2.5 mL (1/2 measuring spoon) of gel applied four times a day after meals.</li></ul></li><li><strong>Also advise that:</strong><ul><li>The gel should not be swallowed immediately but kept in the mouth as long as possible.</li><li>The treatment should be continued for at least 7 days after the symptoms have disappeared.</li><li>Dental prostheses should be removed at night and brushed with the gel.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>] </p><!-- end field 6f406926-0668-4139-ae2e-a76000a20ab8 --><!-- end item 52200db4-9712-4d03-a2b7-a76000a20b1b -->","subChapters":[]},{"id":"d985923b-1fa9-5099-a8e5-066fd0bb4aa2","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field efcc3718-d149-429f-b466-a76000a22b95 --><h3>What are the contraindications and cautions?</h3><!-- end field efcc3718-d149-429f-b466-a76000a22b95 -->","summary":"","htmlStringContent":"<!-- begin item 7d66ef28-0800-493c-870d-a76000a22c3b --><!-- begin field af7de3ab-466b-4d3c-b3c5-a76000a22b95 --><ul><li><strong>Do not prescribe miconazole oral gel to:</strong><ul><li>Children whose swallowing reflex is not yet sufficiently developed.</li><li>People with liver dysfunction.</li></ul></li><li><strong>Prescribe miconazole oral gel with caution to:</strong><ul><li>Children aged under 4 months (or younger than 5–6 months for pre-term children) — this is an unlicensed indication.</li><li>Children aged 4 months – 2 years.<ul><li>Take into consideration the variability of the maturation of the swallowing function in infants, especially when giving miconazole gel to infants aged 4–6 months.</li><li>Advise parents and/or carers that the gel should not be applied to the back of the throat; that each dose should be divided into smaller portions and applied into the mouth with a clean finger; and to observe the child for possible choking.</li></ul></li><li>Pregnant women.<ul><li>The manufacturer advises that miconazole oral gel should be avoided in pregnant women if possible. The potential hazards should be balanced against the possible benefits. In animal studies, miconazole has shown no teratogenic effects but is foetotoxic at high oral doses.</li></ul></li><li>Breastfeeding women.<ul><li>The manufacturer advises that caution should be exercised when miconazole oral gel is prescribed for a breastfeeding woman, as it is not known whether it is excreted in human milk.</li><li>Advise that, due to the risk of choking, the gel must not be applied to the nipple for administration to an infant.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>] </p><!-- end field af7de3ab-466b-4d3c-b3c5-a76000a22b95 --><!-- end item 7d66ef28-0800-493c-870d-a76000a22c3b -->","subChapters":[]},{"id":"84baf4d4-5076-5ac3-bda6-455a77f60cc1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a03492b1-4dc9-4eeb-87ad-a76000a24a89 --><h3>What are the possible adverse effects?</h3><!-- end field a03492b1-4dc9-4eeb-87ad-a76000a24a89 -->","summary":"","htmlStringContent":"<!-- begin item 726c4c49-e1bf-4304-bbea-a76000a24b69 --><!-- begin field 67a4e5cb-1ae9-4612-b09a-a76000a24a89 --><ul><li><strong>Common adverse effects of miconazole oral gel include</strong> dry mouth, nausea, oral discomfort, vomiting, and regurgitation.</li><li><strong>Other adverse effects include:</strong><ul><li><strong>Uncommon </strong>— dysgeusia.</li><li><strong>Frequencies unknown </strong>— anaphylactic reaction, hypersensitivity, choking, diarrhoea, stomatitis, tongue discolouration, hepatitis, angio-oedema, urticaria, rash, acute generalised exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms.</li></ul></li><li><strong>Serious skin reactions</strong> (such as toxic epidermal necrolysis and Stevens-Johnson syndrome) have also been reported.<ul><li>Inform the person about the signs of serious skin reactions, and advise that they should discontinue treatment and seek specialist advice at the first appearance of a skin rash.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>] </p><!-- end field 67a4e5cb-1ae9-4612-b09a-a76000a24a89 --><!-- end item 726c4c49-e1bf-4304-bbea-a76000a24b69 -->","subChapters":[]},{"id":"3a8bddea-91a4-5f0c-84f0-316f18910487","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 03bd8e6c-d4e9-41b1-b0a4-a76000a26f77 --><h3>What drug interactions are associated with miconazole oral gel?</h3><!-- end field 03bd8e6c-d4e9-41b1-b0a4-a76000a26f77 -->","summary":"","htmlStringContent":"<!-- begin item 519d3493-6db1-4246-a5c9-a76000a26f6d --><!-- begin field 58bd3ad7-44e3-4686-8c85-a76000a26f77 --><ul><li><strong>Miconazole can inhibit the metabolism of drugs metabolized by the CYP3A4 and CYP2C9 enzyme systems, resulting in an increase and/or prolongation of their effects, including adverse effects.</strong><ul><li><strong>Concurrent treatment with miconazole oral gel and the following drugs is contraindicated </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]<strong>: </strong><ul><li>Drugs known to prolong the QT-interval, for example mizolastine and pimozide.</li><li>Ergotamine — increased risk of ergotism when imidazoles are given with ergotamine.</li><li>Simvastatin — possible increased risk of myopathy when miconazole is given with simvastatin.</li><li>Quetiapine. </li><li>Triazolam and oral midazolam.</li><li>Warfarin. The manufacturers summary of products characteristics details the interaction with warfarin which has been updated to state that patients should not use if they are taking warfarin. Concomitant use can substantially increase INR, and fatal outcomes (due to bleeding) have been reported. See the <a href=\"http://www.medicines.org.uk/emc/medicine/22032\" data-hyperlink-id=\"9c2fc4a0-3bc7-4b75-9e21-a9a600d40894\">SPC here</a>. </li></ul></li><li><strong>Concurrent treatment with miconazole oral gel and the following drugs should be done with caution or avoided if possible </strong>(concurrent use should be monitored; dose adjustments may be indicated) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]:<ul><li>Carbamazepine — miconazole possibly increases plasma concentration of carbamazepine.</li><li>Certain calcium channel blockers (such as dihydropyridines and verapamil).</li><li>Ciclosporin — miconazole possibly inhibits metabolism of ciclosporin (increased plasma concentration).</li><li>HIV Protease Inhibitors (such as saquinavir).</li><li>Phenytoin and fosphenytoin — miconazole enhances anticonvulsant effect of these drugs, leading to an increased plasma concentration.</li><li>Reboxetine — avoidance of imidazoles is advised by the manufacturer of reboxetine.</li><li>Sulphonylureas — miconazole enhances the hypoglycaemic effect of sulphonylureas (such as gliclazide and glipizide). If concurrent treatment is necessary, advise the person to seek medical advice if they have symptoms of hypoglycaemia (for example nervousness, sweating, and/or trembling) during concurrent treatment.</li><li>Tacrolimus and sirolimus — miconazole oral gel possibly increases plasma concentration of tacrolimus, and increases plasma concentration of sirolimus.</li></ul></li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions of miconazole oral gel</strong><strong>, </strong>see the <a data-hyperlink-id=\"4e6664e6-0e75-404c-8a65-a98f0186e821\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"e7040e84-a7fd-4a00-8e66-a98f0186e84b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field 58bd3ad7-44e3-4686-8c85-a76000a26f77 --><!-- end item 519d3493-6db1-4246-a5c9-a76000a26f6d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}